ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 184 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201,373 | -69.2% | 18,028 | +30.2% | 0.03% | -56.2% |
| Q2 2022 | $654,000 | +171.4% | 13,843 | +391.8% | 0.06% | +276.5% |
| Q3 2018 | $241,000 | -37.2% | 2,815 | -15.0% | 0.02% | -10.5% |
| Q2 2018 | $384,000 | +43.3% | 3,311 | 0.0% | 0.02% | +35.7% |
| Q1 2018 | $268,000 | – | 3,311 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 1,055,719 | $35,367,000 | 12.68% |
| GREAT POINT PARTNERS LLC | 828,253 | $27,746,000 | 5.70% |
| McClain Value Management LLC | 116,153 | $3,891,000 | 4.80% |
| Stonepine Capital Management, LLC | 231,913 | $7,769,000 | 4.63% |
| ARMISTICE CAPITAL, LLC | 228,000 | $7,638,000 | 1.81% |
| Opaleye Management Inc. | 90,000 | $3,015,000 | 1.78% |
| Matarin Capital Management, LLC | 257,268 | $8,618,478,000 | 0.97% |
| HAYS ADVISORY LLC | 116,939 | $3,917,000 | 0.87% |
| Granahan Investment Management | 496,025 | $16,617,000 | 0.57% |
| AlphaMark Advisors, LLC | 33,000 | $1,106,000 | 0.57% |